Rongfeng Fu

Rongfeng Fu

Auto-generated profile, based on publicly available information

Rongfeng Fu

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2024 in British Journal of Haematology
Verified
Journal Article
Open access
SSShanshan Suo
Shanshan Suo
RFRong Feng Fu
Rong Feng Fu
AQAlbert Qin
Albert Qin
ZSZonghong Shao
Zonghong Shao
JBJie Bai
Jie Bai
JJJie Jin
Jie Jin

28 March 2023 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
WGWenjing Gu
Wenjing Gu
YZYuhui Zhang
Yuhui Zhang
TSTing Sun
Ting Sun
MJMankai Ju
Mankai Ju
XLXiaofan Liu
Xiaofan Liu
LZLei Zhang
Lei Zhang
Thrombosis is an important cause of death in patients with polycythemia vera (PV). The conventional stratification of thrombosis may ignore some potential risk factors. This study aimed to develop and validate a multiple factor-based prediction model of thrombosis for the 2016 World Health Organization-dened PV. Clinical and next-generation sequencing data from 2 cohorts of patients with PV were analyzed. Multivariable Cox regression analyses were conducted for the identification of thrombotic risk factors and model development. The study involved 372 patients in the training cohort and another 195 patients in the external validation cohort. Multivariable analyses indicated that age ≥60 years (hazard ratio [HR] 2.56, 95% CI 1.51-4.35, P < .001), cardiovascular risk factors (HR 4.22, 95% CI 2.00-8.92, P < .001), at least 1 high-risk mutation for thrombosis (mutations in DNMT3A, ASXL1, or BCOR/BCORL1) (HR 4.35, 95% CI 2.62-7.21, P < .001), and previous thrombosis (HR 5.93, 95% CI 3.29-10.68, P < .001) were independent risk factors of thrombosis. After assigning coefficient-weighted scores to each risk factor mentioned above, a multiple factor-based prognostic score system of thrombosis (MFPS-PV) was developed, classifying patients into low-risk, intermediate-risk, and high-risk groups. Patients in the 3 groups had notably different thrombosis-free survival rates (P < .001). The MFPS-PV outperformed the conventional model in discrimination power (C-statistic: 0.87 [95% CI 0.83-0.91] vs 0.80 [95% CI 0.74-0.86]). The MFPS-PV was well calibrated and remained consistent during external validation. The MFPS-PV, integrating genetic and clinical characteristics for the first time, shows excellent accuracy and utility for thrombosis prediction in WHO-defined PV.

4 March 2024 in British Journal of Haematology
Verified
Journal Article
Closed access
YLYang Li
Yang Li
TSTing Sun
Ting Sun
JCJia Chen
Jia Chen
XLXiaofan Liu
Xiaofan Liu
RFRongfeng Fu
Rongfeng Fu
LZLei Zhang
Lei Zhang

17 January 2024 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
DYDandan Yu
Dandan Yu
FXFeng Xue
Feng Xue
XLXiaofan Liu
Xiaofan Liu
YCYunfei Chen
Yunfei Chen
RFRongfeng Fu
Rongfeng Fu
LZLei Zhang
Lei Zhang
Acquired hemophilia A (AHA) is a rare hemorrhagic disorder caused by factor (F)VIII inhibitors. The diagnosis and management of AHA remains challenging because of its rarity and heterogeneity. To analyze the characteristics of AHA to enhance our understanding of this disease and identify effective treatment strategies. To analyze the characteristics of AHA to enhance our understanding of this disease and identify effective treatment strategies. Clinical features of 165 patients with AHA from a single center between July 1997 and December 2021 were retrospectively analyzed. The median age of patients at diagnosis was 45 years. The median time to diagnosis was 30 days. All 165 patients experienced bleeding, with a median bleeding score (BS) of 4 (range, 2-12). Hemostatic therapy was administered to 129 (78.2%) patients. Bleeding control was achieved in 80.0% of patients who received prothrombin complex concentrate and in 92.3% of patients who were treated with recombinant activated FVII. Of the 163 patients who received immunosuppressive therapy, 80 (49.1%) received rituximab-based therapy with a 93.3% complete remission (CR) rate, 50 (30.7%) received steroids plus cyclophosphamide with an 85.0% CR rate, and 22 (13.5%) received steroids alone with an 82.4% CR rate. Six cases relapsed after a median duration of 330 days. Immunosuppressive therapy–related adverse events were reported in 17 patients. Seven deaths were recorded. FVIII inhibitor titer of ≥15 BU/mL and BS of ≥6 were identified as significantly poor prognostic factors for CR. Immunosuppressive therapies yield remarkably high response rates, with a CR rate exceeding 80%; notably, the regimen containing rituximab exhibits a CR rate of approximately 90%. FVIII inhibitor titer of ≥5 BU/mL and BS of ≥6 were poor predictors of CR in patients with AHA.

14 February 2023 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
WLWei Liu
Wei Liu
FXFeng Xue
Feng Xue
RFRongfeng Fu
Rongfeng Fu
BDBingjie Ding
Bingjie Ding
MLMengjuan Li
Mengjuan Li
LZLei Zhang
Lei Zhang
Bleeding episodes in hemophiliacs with inhibitors are difficult to control. Staidson protein-0601 (STSP-0601), a specific factor (F)X activator purified from the venom of Daboia russelii siamensis, has been developed. We aimed to investigate the efficacy and safety of STSP-0601 in preclinical and clinical studies. In vitro and in vivo preclinical studies were performed. A phase 1, first-in-human, multicenter, and open-label trial was conducted. The clinical study was divided into parts A and B. Hemophiliacs with inhibitors were eligible for this study. Patients received a single intravenous injection of STSP-0601 (0.01 U/kg, 0.04 U/kg, 0.08 U/kg, 0.16 U/kg, 0.32 U/kg, or 0.48 U/kg) in part A or a maximum of 6 4-hourly injections (0.16 U/kg) in part B. The primary endpoint for each part was the number of adverse events (AEs) from baseline to 168 hours after administration. This study was registered at clinicaltrials.gov (NCT-04747964 and NCT-05027230). Preclinical studies showed that STSP-0601 could specifically activate FX in a dose-dependent manner. In the clinical study, 16 patients in part A and 7 patients in part B were enrolled. Eight (22.2%) AEs in part A and 18 (75.0%) AEs in part B were reported to be related to STSP-0601. Neither severe AEs nor dose-limiting toxicity events were reported. There were no thromboembolic event. The antidrug antibody of STSP-0601 was not detected. Preclinical and clinical studies showed that STSP-0601 had a good ability to activate FX and had a good safety profile. STSP-0601 could be used as a hemostatic treatment in hemophiliacs with inhibitors.

10 April 2023 in Thrombosis Research
Verified
Journal Article
Closed access
HDHuan Dong
Huan Dong
HLHuiyuan Li
Huiyuan Li
LFLijun Fang
Lijun Fang
AZAnqi Zhang
Anqi Zhang
XLXiaofan Liu
Xiaofan Liu
LZLei Zhang
Lei Zhang